Avidity Partners Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Avidity Partners Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,400	Closed	-$16.1M	–	79
2025 Q1	$16.1M	Buy	25,400 +17,000	+202%	+$11.7M	3.07%	8
2024 Q4	$5.98M	Buy	+8,400	New	+$7.05M	0.59%	49
2024 Q3	–	Sell	-48,000	Closed	-$50.4M	–	99
2024 Q2	$50.4M	Sell	48,000 -20,000	-29%	-$19.4M	2.14%	13
2024 Q1	$65.4M	Hold	68,000	–	–	2.11%	14
2023 Q4	$59.7M	Buy	68,000 +10,000	+17%	+$8.23M	2.18%	14
2023 Q3	$47.7M	Buy	58,000 +33,200	+134%	+$26.1M	1.92%	16
2023 Q2	$17.8M	Sell	24,800 -94,300	-79%	-$72.7M	0.62%	56
2023 Q1	$97.9M	Buy	+119,100	New	+$89.8M	3.25%	6
2021 Q4	–	Sell	-152,300	Closed	-$92.2M	–	109
2021 Q3	$92.2M	Buy	+152,300	New	+$94.6M	2.04%	11
2020 Q3	–	Sell	-132,100	Closed	-$82.4M	–	83
2020 Q2	$82.4M	Buy	132,100 +82,100	+164%	+$46.6M	5.28%	2
2020 Q1	$24.4M	Buy	+50,000	New	+$20.6M	3.37%	6

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Avidity Partners Management's REGN Position: Q2 2025 in Review

Avidity Partners Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 25,400 shares — an estimated $16.1M sold.

Avidity Partners Management first reported a position in REGN in Q1 2020 and held it in 11 quarters. The position peaked at $97.9M in Q1 2023. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Avidity Partners Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Avidity Partners Management sold 25,400 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $16.1M.
Avidity Partners Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 11 quarters.
Avidity Partners Management's Regeneron Pharmaceuticals position peaked at $97.9M in Q1 2023.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.